Adenosine Therapeutics Awarded Approximately $1.8M from NIAID
Four grants fund evaluation of therapeutic approaches to asthma, sepsis, and arthritis.!--h2>
Adenosine Therapeutics was awarded four new grants totaling approximately $1,887,634. These grants will help further evaluate new therapeutic approaches for the treatment of asthma, sepsis, and arthritis.
The NIAID funded the grants: a Phase I STTR-AT grant of $861,737 to further expand research on the use of apadenoson, the company's selective A2A agonist that is in Phase III testing as a heart imaging agent for the treatment of sepsis; a Phase II SBIR grant totaling $755,496 to identify an A2BR antagonist as a therapeutic candidate for the treatment of asthma; a Phase I STTR grant for $132,798 to further expand its preclinical research on the use of agents that activate the adenosine A2A receptor subtypes for the treatment of S. aureus sepsis; and a Phase I STTR of $137,603 to further expand its clinical research on the use of agents that activate the adenosine A2A receptor subtypes for the treatment of arthritis.